Clinical trials
Metastatic Head and Neck Cancer clinical trials
Below are recruiting metastatic head and neck cancer clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT03145077Recruiting
MRI test to diagnose jaw bone damage after head and neck radiation
This study uses special MRI scans with contrast to better detect osteoradionecrosis (jaw bone injury) after radiation for head and neck cancer. If you qualify, the scans may help your team diagnose problems earlier and choose the right next treatment.
Houston, TexasAges 18 years+ - NCT03483337Recruiting
MRI scan tests new markers for head and neck cancers
This trial tests special MRI scans to find warning signs of cancer that has returned or spread in the head and neck area. It may help doctors see these changes more clearly, which could improve treatment planning.
New York, New YorkAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+ - NCT07214987RecruitingPhase 2
PDT with immunotherapy and chemo for head and neck cancer
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Boston, MassachusettsAges 18 years+ - NCT04375384RecruitingPhase 2
Cetuximab after immunotherapy for head and neck cancer
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT04498767Recruiting
Radiation to treat a few metastatic spots in rare cancers
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
AnderlechtAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT04868162RecruitingPhase 2
MRG003 for head and neck cancer after prior treatments
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05097625Recruiting
Testing early detection of head and neck cancer relapse
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
LondonAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+
Hear when a new Metastatic Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic head and neck cancer?
- Yes. Clin2 currently lists 260 recruiting metastatic head and neck cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic head and neck cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic head and neck cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Head and Neck Cancer
- Metastatic Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Cancer
- Head and Neck Cancer (H&N)
- Head and Neck Cancer Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Head &Amp; Neck Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.